Groovy Medicine

Groovy Medicine is a Hangzhou-based biotechnology company founded in 2022 that specializes in AI-driven drug discovery through a proprietary high-dimensional biology platform. The company focuses on developing novel therapies for major refractory diseases, particularly in the fields of oncology and neurodegeneration. Its lead candidate, GW01-200, is a first-in-class small molecule inhibitor of the Notch signaling pathway, which entered Phase 1 clinical trials in June 2026 for the treatment of advanced solid tumors. Groovy Medicine leverages innovative computational algorithms to identify novel targets and optimize drug candidates, bridging the gap between complex biological data and clinical application. The company is closely affiliated with West Lake University and is supported by prominent investors including the Betta Pharmaceutical Industry Fund and West Lake Innovation Investment.